Jubilant Biosys Limited, a wholly-owned subsidiary of Jubilant Pharmova Limited and a global CRDMO with operations across India and Europe, has inaugurated a new discovery and preclinical facility in Noida, effectively doubling its chemistry capacity for discovery research and early-phase scale-up projects.
The multimillion-dollar facility integrates discovery labs, early-phase scale-up capabilities, and two pilot plants, addressing rising demand for fee-for-service (FFS) contracts.
Designed to handle quantities ranging from hundreds of grams up to 25 kg, the facility features 20,000 sq. ft. of R&D space and 15 reactors of varying sizes from 20L to 250L. It also allows seamless transfer of projects from discovery to GMP-ready commercial phases.
The new facility complements Jubilant Biosys’ existing Chemistry Research Innovation Centre (CRIC) in Greater Noida, bringing the total scientific workforce across the company to over 1,300 professionals. Multiple manufacturing lines have been added to support growing client demand, and the facility has been designed with future scalability in mind, allowing capacity to quadruple as needed.
This expansion strengthens Jubilant Biosys’ integrated discovery-to-scale-up offerings, enabling faster project delivery, enhanced operational efficiency, and support for global biotech and pharmaceutical partners in early-stage research and development.
